These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36325394)

  • 21. Peptide-Based Covalent Inhibitors Bearing Mild Electrophiles to Target a Conserved His Residue of the Bacterial Sliding Clamp.
    Compain G; Monsarrat C; Blagojevic J; Brillet K; Dumas P; Hammann P; Kuhn L; Martiel I; Engilberge S; Oliéric V; Wolff P; Burnouf DY; Wagner J; Guichard G
    JACS Au; 2024 Feb; 4(2):432-440. PubMed ID: 38425897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The expanding repertoire of covalent warheads for drug discovery.
    Mehta NV; Degani MS
    Drug Discov Today; 2023 Dec; 28(12):103799. PubMed ID: 37839776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysine-Targeting Covalent Inhibitors.
    Pettinger J; Jones K; Cheeseman MD
    Angew Chem Int Ed Engl; 2017 Nov; 56(48):15200-15209. PubMed ID: 28853194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation.
    Zhang T; Hatcher JM; Teng M; Gray NS; Kostic M
    Cell Chem Biol; 2019 Nov; 26(11):1486-1500. PubMed ID: 31631011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and optimization of covalent Bcl-xL antagonists.
    Mukherjee H; Su N; Belmonte MA; Hargreaves D; Patel J; Tentarelli S; Aquila B; Grimster NP
    Bioorg Med Chem Lett; 2019 Dec; 29(23):126682. PubMed ID: 31606346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics.
    Li Q; Chen Q; Klauser PC; Li M; Zheng F; Wang N; Li X; Zhang Q; Fu X; Wang Q; Xu Y; Wang L
    Cell; 2020 Jul; 182(1):85-97.e16. PubMed ID: 32579975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced approaches of developing targeted covalent drugs.
    Gai C; Harnor SJ; Zhang S; Cano C; Zhuang C; Zhao Q
    RSC Med Chem; 2022 Dec; 13(12):1460-1475. PubMed ID: 36561076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Advances in applications of activity-based chemical probes in the characterization of amino acid reactivities].
    Li J; Wang G; Ye M; Qin H
    Se Pu; 2023 Jan; 41(1):14-23. PubMed ID: 36633073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Catalyst-free late-stage functionalization to assemble α-acyloxyenamide electrophiles for selectively profiling conserved lysine residues.
    Zhao Y; Duan K; Fan Y; Li S; Huang L; Tu Z; Sun H; Cook GM; Yang J; Sun P; Tan Y; Ding K; Li Z
    Commun Chem; 2024 Feb; 7(1):31. PubMed ID: 38355988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and biological applications of sulfur-triazole exchange (SuTEx) chemistry.
    Borne AL; Brulet JW; Yuan K; Hsu KL
    RSC Chem Biol; 2021 Apr; 2(2):322-337. PubMed ID: 34095850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A study of the reactivity of S
    Mukherjee H; Debreczeni J; Breed J; Tentarelli S; Aquila B; Dowling JE; Whitty A; Grimster NP
    Org Biomol Chem; 2017 Nov; 15(45):9685-9695. PubMed ID: 29119993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lysine-Reactive
    Kawano M; Murakawa S; Higashiguchi K; Matsuda K; Tamura T; Hamachi I
    J Am Chem Soc; 2023 Dec; 145(48):26202-26212. PubMed ID: 37987622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors.
    Liu R; Yue Z; Tsai CC; Shen J
    J Am Chem Soc; 2019 Apr; 141(16):6553-6560. PubMed ID: 30945531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein Arginine Deiminases (PADs): Biochemistry and Chemical Biology of Protein Citrullination.
    Mondal S; Thompson PR
    Acc Chem Res; 2019 Mar; 52(3):818-832. PubMed ID: 30844238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetically Encoding Fluorosulfate-l-tyrosine To React with Lysine, Histidine, and Tyrosine via SuFEx in Proteins in Vivo.
    Wang N; Yang B; Fu C; Zhu H; Zheng F; Kobayashi T; Liu J; Li S; Ma C; Wang PG; Wang Q; Wang L
    J Am Chem Soc; 2018 Apr; 140(15):4995-4999. PubMed ID: 29601199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrated Covalent Drug Design Workflow Using Site Identification by Ligand Competitive Saturation.
    Yu W; Weber DJ; MacKerell AD
    J Chem Theory Comput; 2023 May; 19(10):3007-3021. PubMed ID: 37115781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategic Design of Catalytic Lysine-Targeting Reversible Covalent BCR-ABL Inhibitors*.
    Quach D; Tang G; Anantharajan J; Baburajendran N; Poulsen A; Wee JLK; Retna P; Li R; Liu B; Tee DHY; Kwek PZ; Joy JK; Yang WQ; Zhang CJ; Foo K; Keller TH; Yao SQ
    Angew Chem Int Ed Engl; 2021 Jul; 60(31):17131-17137. PubMed ID: 34008286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global targeting of functional tyrosines using sulfur-triazole exchange chemistry.
    Hahm HS; Toroitich EK; Borne AL; Brulet JW; Libby AH; Yuan K; Ware TB; McCloud RL; Ciancone AM; Hsu KL
    Nat Chem Biol; 2020 Feb; 16(2):150-159. PubMed ID: 31768034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetic Optimization of Lysine-Targeting Covalent Inhibitors of HSP72.
    Pettinger J; Carter M; Jones K; Cheeseman MD
    J Med Chem; 2019 Dec; 62(24):11383-11398. PubMed ID: 31725295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing irreversible inhibitors of the protein kinase cysteinome.
    Liu Q; Sabnis Y; Zhao Z; Zhang T; Buhrlage SJ; Jones LH; Gray NS
    Chem Biol; 2013 Feb; 20(2):146-59. PubMed ID: 23438744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.